DEXCEL: labeling supplement approved for TOFACITINIB CITRATE
DEXCEL: labeling supplement approved for TOFACITINIB CITRATE. Dated 9 days ago, it is in the active follow-up window. Score 65/100. As of 2026-11-03, from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration).
Data as of · Compiled by Zalwin from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)
Free preview: all 7 published fields of this record are shown below. Locked: 499 related FdaApprovalPulse records and the 4-column CSV export.
| Field | Value |
|---|---|
| Sponsor | DEXCEL |
| Product | TOFACITINIB CITRATE |
| Generic / ingredient | TOFACITINIB CITRATE |
| Approval | Drug labeling or REMS supplement |
| Application | ANDA218668 supplement 3 |
| Decided | 2026-10-26 |
| Panel / class | TABLET, EXTENDED RELEASE, ORAL |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch DEXCEL
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock DEXCEL + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Product · Approval · Decided · official source URL
- Source agency: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)
- Record date: 2026-10-26
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top FdaApprovalPulse records: Instylla, Inc. · Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Cerenovus, Inc. · Advanced Medical Solutions Limited · Lenstec, Inc. · Browse all by state and category →
LIVE PUBLIC DATA Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) · Last refreshed: Tue, 03 Nov 2026 05:14:00 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
65 / 100 Score
- Decided in the last 30 days.
- New labeling to print and distribute.
What is the FdaApprovalPulse record for DEXCEL?
The FDA approved TOFACITINIB CITRATE (ANDA218668 supplement 3) for DEXCEL on 2026-10-26: drug labeling or REMS supplement.
How does DEXCEL compare to other FdaApprovalPulse records?
It is fresh: dated 9 days ago, inside the window where early outreach matters most.
DEXCEL vs. top 3 peers
| Organization | Record date |
|---|---|
| DEXCEL | 2026-10-26 |
| NOVARTIS | 2026-10-28 |
| ACTELION | 2026-10-27 |
| NATCO PHARMA LTD | 2026-10-27 |
Related records
FdaApprovalPulse: Drug labeling or REMS supplement
How to monitor DEXCEL and peer drug labeling or rems supplement records
Get new FdaApprovalPulse records like DEXCEL by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new approvals in your categories
FdaApprovalPulse emails new device and drug approvals matching your approval types.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.